Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.

Literature DB >> 6678857

Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.

C A Coltman, T M McDaniel, S P Balcerzak, F S Morrison, D D Von Hoff.

Abstract

The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (3/13 responses in Hodgkin's; 9/37 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1983 PMID： 6678857 DOI： 10.1007/bf00180193

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

8 in total

1. Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA.

Authors: J C Double; J R Brown
Journal: J Pharm Pharmacol Date: 1976-02 Impact factor: 3.765

Review 2. Daunomycin: an anthracycline antibiotic effective in acute leukemia.

Authors: D D Von Hoff; M Rozencweig; M Slavik
Journal: Adv Pharmacol Chemother Date: 1978

3. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

Authors: D D Von Hoff; M Rozencweig; M Layard; M Slavik; F M Muggia
Journal: Am J Med Date: 1977-02 Impact factor: 4.965

4. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.

Authors: B M Henderson; W J Dougherty; V C James; L P Tilley; J F Noble
Journal: Cancer Treat Rep Date: 1982-05

5. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology.

Authors: B M Sparano; G Gordon; C Hall; M J Iatropoulos; J F Noble
Journal: Cancer Treat Rep Date: 1982-05

6. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.

Authors: D D Von Hoff; E Pollard; J Kuhn; E Murray; C A Coltman
Journal: Cancer Res Date: 1980-05 Impact factor: 12.701

7. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.

Authors: R E Wallace; K C Murdock; R B Angier; F E Durr
Journal: Cancer Res Date: 1979-05 Impact factor: 12.701

8. Activity of mitoxantrone in a human tumor cloning system.

Authors: D D Von Hoff; C A Coltman; B Forseth
Journal: Cancer Res Date: 1981-05 Impact factor: 12.701

8 in total

11 in total

1. VIM-D salvage chemotherapy in Hodgkin's disease.

Authors: J K Phillips; R L Spearing; J M Davies; C R Hay; H Parry; J R Nash; J C Cawley
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

2. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.

Authors: M Dietel; H Arps; D Gerding; M Trapp; M Sieck; A Niendorf
Journal: J Cancer Res Clin Oncol Date: 1988 Impact factor: 4.553

10. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.

Authors: S J Van Belle; M M de Planque; I E Smith; A T van Oosterom; T J Schoemaker; W Deneve; J G McVie
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.

1. Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA.

Review 2. Daunomycin: an anthracycline antibiotic effective in acute leukemia.

3. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

4. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.

5. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology.

6. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.

7. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.

8. Activity of mitoxantrone in a human tumor cloning system.

1. VIM-D salvage chemotherapy in Hodgkin's disease.

2. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.

3. Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

4. Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.

5. The pharmacokinetics and metabolism of mitoxantrone in man.

6. A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck.

7. Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.

8. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.

9. Phase II trial of mitoxantrone in head and neck cancer.

10. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.